• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Clinical characteristics of painful dystonic foot response in patients with Parkinson's disease].

作者信息

Hara H, Wakayama Y, Kawase J

出版信息

Rinsho Shinkeigaku. 1989 Sep;29(9):1101-5.

PMID:2598534
Abstract

We analyzed clinical characteristics of painful dystonic foot response (PDFR) which was observed in 7 patients with Parkinson's disease during levodopa therapy. PDFR was divided into 3 types, (1) early morning type (2) end of dose type (3) peak dose type, according to the serum levodopa concentration and clinical picture. Four patients showed different type of PDFR during observation. Provocative factors included stimulations to sole such as sacking or standing, abrupt change of mode of levodopa administration. Clonazepam ameliorated markedly the frequency and severity of PDFR in 3 out of 4 patients. Several trials to reduced fluctuation of the serum levodopa concentration such as fractionation into small doses and frequent administration, and to use of levodopa alone instead of dopa-decarboxylase inhibitor combined tablet, failed to show improvement and gave rather transient aggravation. For the control of PDFR most important thing was the reduction of dosage of levodopa. The efforts to avoid the above provocative factor are also needed. If the patient suffered from the frequent PDFR attack, the PDFR ameliorating drugs such as clonazepam would be useful.

摘要

相似文献

1
[Clinical characteristics of painful dystonic foot response in patients with Parkinson's disease].
Rinsho Shinkeigaku. 1989 Sep;29(9):1101-5.
2
"Off" painful dystonia in Parkinson's disease treated with botulinum toxin.肉毒杆菌毒素治疗帕金森病中的“关闭期”疼痛性肌张力障碍
Mov Disord. 1995 May;10(3):333-6. doi: 10.1002/mds.870100317.
3
Complex dystonia of Parkinson's disease: clinical features and relation to plasma levodopa profile.帕金森病的复杂性肌张力障碍:临床特征及其与血浆左旋多巴水平的关系。
Clin Neuropharmacol. 1990 Apr;13(2):164-70.
4
Dystonia in Parkinson's disease: clinical and pharmacological features.帕金森病中的肌张力障碍:临床和药理学特征
Ann Neurol. 1988 Jan;23(1):73-8. doi: 10.1002/ana.410230112.
5
[Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].左旋多巴无脱羧酶抑制剂疗法对帕金森病患者晚期剂末现象的益处
No To Shinkei. 2002 Feb;54(2):127-32.
6
Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology.帕金森病中左旋多巴诱发的异动症:现象学与病理生理学
Mov Disord. 1994 Jan;9(1):2-12. doi: 10.1002/mds.870090103.
7
Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model.帕金森病运动波动的突触前机制:一个概率模型
Brain. 2004 Apr;127(Pt 4):888-99. doi: 10.1093/brain/awh102. Epub 2004 Feb 11.
8
Sustained low-dose levodopa therapy in Parkinson's disease: a 3-year follow-up.帕金森病的持续小剂量左旋多巴治疗:3年随访
Adv Neurol. 1983;37:9-15.
9
The impact of treatment with levodopa on Parkinson's disease.左旋多巴治疗对帕金森病的影响。
Q J Med. 1980;49(195):283-93.
10
[Dystonia preceding dopa-responsive parkinsonism--heterogeneous clinical features].[多巴反应性帕金森综合征之前的肌张力障碍——临床特征异质性]
No To Shinkei. 1996 Feb;48(2):149-54.